Pharmaceutical giants celebrated the dawn of 2020 in the best way they know how: jacking up the prices of drugs for people in the US that need them.
, research by analysts at 3 Axis Advisors shows that firms including Pfizer Inc., GlaxoSmithKline PLC, Sanofi SA, Bristol-Myers Squibb Co., Gilead Sciences Inc., and Biogen Inc. have collectively raised U.S. prices on 250 drugs since the ball dropped on New Year’s Eve. The median price increase is around five percent, Reuters wrote, while few of the drugs had price increases of (percent or more.)
Thousands of drugs saw price increases last year, according to analysisby Rx Savings Solutions, which found a 11. 5 percent average increase across 3, separate medications (that’s over five times the rate of inflation). Insurers and patients often avoid paying the full list prices of medication due to negotiated deals between manufacturers and buyers, though that’s far from certain to cover the costs, especially for the uninsured, those on insurance that refuses to cover certain drugs, or those on plans that increasingly charge percentage-based coinsurance instead of copays for prescriptions. (AsConsumer Reports reportedlast year, insurers often calculate the percentage based on the list price of the drug rather than the negotiated price.)
A Kaiser Family Foundation survey last year found that [[“Embedded Url”,”External link”,”https://www.npr.org/sections/health-shots/2019/12/31/792617538/a-decade-marked-by-outrage-over-drug-prices”,{“metric25”:1}](percent of respondents
had failed to take prescriptions as directed by medical personnel in the prior 12 months due to cost issues. As Reuters noted, the US’s market pricing model for drugs means that they cost far more than in other nations with more government control (which has also made the US the pharmaceutical industry’s single most lucrative nation).
GIPHY App Key not set. Please check settings